Turning Point Therapeutics, Inc.
NASDAQ: TPTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Athena Maria Countouriotis
- Employees
- 267
- Headquarters
- San Diego, United States
- IPO year
- 2019
- Website
- https://www.tptherapeutics.com
Loading TPTX…
Loading profile data…Frequently asked questions about TPTX
What does Turning Point Therapeutics, Inc. (TPTX) do?
Turning Point Therapeutics is a biopharmaceutical firm specializing in precision oncology, currently in the clinical development stage. The company is dedicated to discovering and advancing targeted therapies that address the underlying genetic causes of cancer. They have developed a portfolio of innovative tyrosine kinase inhibitors (TKIs) desi...
Where does TPTX trade?
Turning Point Therapeutics, Inc. (TPTX) trades on the NASDAQ Global Select.
What sector is TPTX in?
Turning Point Therapeutics, Inc. (TPTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Turning Point Therapeutics, Inc.?
Athena Maria Countouriotis is the chief executive officer of Turning Point Therapeutics, Inc. (TPTX).
Where is Turning Point Therapeutics, Inc. headquartered?
Turning Point Therapeutics, Inc. is headquartered in United States.
Does TPTX pay a dividend?
Turning Point Therapeutics, Inc. (TPTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TPTX go public?
Turning Point Therapeutics, Inc. (TPTX) completed its initial public offering in 2019.